Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00250094 · ClinicalTrials.gov registry record · Phase 1
Clinical Benefit of Topoisomerase Downregulation
A Phase 1 study, sponsored by New Mexico Cancer Research Alliance.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00250094 is a Phase 1 study that has completed, run by New Mexico Cancer Research Alliance. The registered enrollment target is 15 participants.
The verdict
NCT00250094, a Phase 1 study, has completed, sponsored by New Mexico Cancer Research Alliance.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
1.1 To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16) 1.2 To determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.
Interventions
- DRUG Topotecan and VP16
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00250094
The ClinicalTrials.gov registry entry for NCT00250094 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New Mexico Cancer Research Alliance, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Topotecan and VP16 is the first listed.
NCT00250094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00250094 about?
NCT00250094 is a clinical study titled "Clinical Benefit of Topoisomerase Downregulation". 1.1 To determine the regulation of topoisomerase I and II following alternating prolonged exposure to topotecan and etoposide (VP-16) 1.2 To determine the time to progression and the objective response rate of this treatment in patients with incurable ovarian cancer.
What is the current status of trial NCT00250094?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2004-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00250094?
The interventions under investigation include: Topotecan and VP16 (DRUG).
Who is sponsoring clinical trial NCT00250094?
This trial is sponsored by New Mexico Cancer Research Alliance, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.